Skip to main content

Table 3 Frequently reported treatment-emergent adverse events

From: Factors influencing treatment outcome in patients with gastroesophageal reflux disease: outcome of a prospective pragmatic trial in Asian patients

MedDRA preferred term

Asia (N = 210), n (%)

Rest of the world (N = 1718), n (%)

Diarrhea

11 (5.2)

47 (2.7)

Upper respiratory tract infection

7 (3.3)

8 (0.5)

Nasopharyngitis

6 (2.9)

10 (0.6)

Headache

3 (1.4)

69 (4.0)

Vomiting

3 (1.4)

10 (0.6)

Constipation

2 (1.0)

18 (1.0)

Heart rate increased

2 (1.0)

0 (0.0)

Insomnia

2 (1.0)

13 (0.8)

Nausea

0 (0.0)

33 (1.9)

Abdominal pain

1 (0.5)

22 (1.3)

Influenza

0 (0.0)

19 (1.1)

  1. A comparison of Asian populations with the rest of the world (intent-to-treat population, N = 210).